Meiragtx Holdings Plc (MGTX) Stock Price, Quote & News

Company Profile

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RP...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 860 7985

Website: www.meiragtx.com

Address:

655 Third Avenue, Suite 1115, New York, United States

MGTX Apr. 25 at 6:22 PM

$MGTX Here’s a question, given the botavec purchase, the GLp-1 preclinical trial, the pivotal phase 2 Xerostomia later this year and more… When will MGTX finally get its bidding war? My best guess is q4 this year Sanofi buys them out cheap or middle of next year. Hoping that Perceptive Advisors protects against a low price…

2 · Reply

slinghook67 Apr. 24 at 5:02 PM

$MGTX This was a great find by Ernie and it's worth a listen in its entirety as Hologen and Meira's Parkinson's program are extensively discussed... https://open.spotify.com/episode/0xDMNbzjsCOfIKxMnnJndA?si=_WiRiHwkTwusNI6ZcHwEIw

0 · Reply

ErnieWorthing84 Apr. 24 at 4:00 PM

$MGTX https://www.fiercebiotech.com/biotech/frenzied-feeding-playing-defense-and-disruption-lillys-kelonia-acquisition-and-future-vivo?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=0316A4496778F6E

0 · Reply

focafoca99 Apr. 24 at 1:54 PM

$MGTX formalizes the initial closing of its Hologen collaboration covering neuro programs, delivery-device rights, and manufacturing arrangements.

0 · Reply

ErnieWorthing84 Apr. 24 at 9:49 AM

$MGTX "AI can change healthcare economics by cutting trial time, improving patient selection, and reducing development cost • The next big winners may not be pure drug companies, but platforms that reshape care delivery and decision-making" https://www.linkedin.com/posts/dweisburd_healthcare-lifesciences-biotech-ugcPost-7452721913518473216-iJNH?utm_source=share&utm_medium=member_desktop&rcm=ACoAAA-izPIBXISQ360qmHAvSKAoz0ecqKOipGs

0 · Reply

slinghook67 Apr. 24 at 2:22 AM

$MGTX Repriced warrants for Perceptive tied to the loan term extension they recently approved, in addition to ~$5M newly purchased shares via last weeks offering. Another confirmatory signal of conviction from Mr. Edelman.

0 · Reply

ErnieWorthing84 Apr. 23 at 10:04 AM

$MGTX CBER candidate… https://x.com/houmanhemmati/status/2047172768488378835

1 · Reply

erevnon Apr. 22 at 1:56 PM

Piper Sandler maintains MeiraGTx Holdings $MGTX at Overweight and raises the price target from $26 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ErnieWorthing84 Apr. 22 at 11:54 AM

$MGTX https://x.com/medtechmd/status/2046910898217029861

0 · Reply

StreetwiseReports Apr. 20 at 8:07 PM

Genetic Medicines Co. Reveals Transformative 'Only-of-Its-Kind' AAV Therapy Milestone https://ow.ly/KsOa50YN3E9 MeiraGTx Holdings Plc ( $MGTX ) reports 3-year gene therapy results, secures US$100M funding, and advances late-stage pipeline, signaling major commercial potential.

0 · Reply

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & Johnson

JNJ LLY

Apr 16, 2026, 8:00 AM EDT - 10 days ago

MeiraGTx Holdings Transcript: KOL event

Apr 16, 2026, 7:47 AM EDT - 10 days ago

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

Apr 16, 2026, 7:10 AM EDT - 10 days ago

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Apr 16, 2026, 7:00 AM EDT - 10 days ago

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

Apr 14, 2026, 8:30 AM EDT - 11 days ago

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

Mar 26, 2026, 8:00 AM EDT - 4 weeks ago

MeiraGTx Announces FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the Treatment of Grade 2 and Grade 3 Radiation-Induced Xerostomia (RIX) and Reports Fourth Quarter and Full Year 2025 Financial and Operational Results

Mar 25, 2026, 11:00 AM EDT - 4 weeks ago

MeiraGTx Holdings Transcript: RBC Capital Markets Virtual Ophthalmology Conference

Feb 3, 2026, 8:00 AM EST - 2 months ago

ZipBio and MeiraGTx Enter into Exclusive License Agreement to Advance First-in-Class AAV Gene Therapy for Geographic Atrophy

Nov 20, 2025, 3:00 PM EST - 5 months ago

Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx Conference

Nov 13, 2025, 8:00 AM EST - 5 months ago

MeiraGTx Reports Third Quarter 2025 Financial and Operational Results

Nov 10, 2025, 9:10 AM EST - 5 months ago

Eli Lilly signs deal for MeiraGTx's gene therapy for severe eye disease

LLY

Nov 10, 2025, 7:00 AM EST - 5 months ago

MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology

Oct 21, 2025, 3:30 PM EDT - 6 months ago

MeiraGTx Holdings Transcript: Chardan’s 9th Annual Genetic Medicines Conference

Oct 7, 2025, 8:00 AM EDT - 7 months ago

MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Aug 14, 2025, 8:00 AM EDT - 9 months ago

MeiraGTx Reports Second Quarter 2025 Financial and Operational Results

May 13, 2025, 4:30 PM EDT - 1 year ago

MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

May 13, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Reports First Quarter 2025 Financial and Operational Results

May 9, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson's Disease

Apr 29, 2025, 7:11 AM EDT - 1 year ago

Cone Rod Dystrophy Market Report 2025-2030, with Profiles of SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, MeiraGTx, Ascidian Therapeutics, jCyte, BlueRock Therapeutics and more

Apr 3, 2025, 11:30 AM EDT - 1 year ago

MeiraGTx Holdings Transcript: RBC Inaugural Virtual Ophthalmology Conference

Mar 13, 2025, 9:51 AM EDT - 1 year ago

MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars

Mar 13, 2025, 8:00 AM EDT - 1 year ago

MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates

Mar 13, 2025, 7:30 AM EDT - 1 year ago

MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process

Feb 21, 2025, 8:00 AM EST - 1 year ago

MeiraGTx Holdings Transcript: Study Update

Feb 21, 2025, 6:30 AM EST - 1 year ago

MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy

Jan 22, 2025, 8:30 AM EST - 1 year ago

MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations

Oct 9, 2024, 4:30 PM EDT - 1 year ago

MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference

Sep 30, 2024, 1:00 PM EDT - 1 year ago

MeiraGTx Holdings Transcript: Chardan's 8th Annual Genetic Medicines Conference

Aug 12, 2024, 7:05 AM EDT - 1 year ago

MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results

Aug 12, 2024, 7:03 AM EDT - 1 year ago

MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi

Jun 12, 2024, 2:40 PM EDT - 2 years ago

MeiraGTx Holdings Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

May 15, 2024, 1:40 PM EDT - 2 years ago

MeiraGTx Holdings Transcript: BofA Securities Health Care Conference 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Apr 29, 2024, 11:00 AM EDT - 2 years ago

MeiraGTx Holdings Transcript: Chardan's 8th Annual Genetic Medicines + Cell Therapy Manufacturing Summit (Virtual)

Apr 24, 2024, 4:30 PM EDT - 2 years ago

MeiraGTx to Participate in Upcoming Investor Conferences

Apr 18, 2024, 4:30 PM EDT - 2 years ago

MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference

Mar 14, 2024, 8:30 AM EDT - 2 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates

Dec 21, 2023, 7:00 AM EST - 2 years ago

MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million

Nov 14, 2023, 8:00 AM EST - 2 years ago

MeiraGTx Announces Third Quarter 2023 Financial and Operational Results

Oct 30, 2023, 8:28 AM EDT - 2 years ago

MeiraGTx shares jump as Sanofi invests in gene therapy

SNY

Oct 30, 2023, 7:30 AM EDT - 2 years ago

MeiraGTx Announces $30 Million Strategic Investment from Sanofi; Company Pursuing Multiple Additional Strategic Opportunities

Oct 24, 2023, 8:30 AM EDT - 2 years ago

MeiraGTx Announces an Oral Presentation and Eight Posters at the European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Aug 10, 2023, 8:00 AM EDT - 2 years ago

MeiraGTx Reports Second Quarter 2023 Financial and Operational Results

Aug 1, 2023, 9:10 AM EDT - 2 years ago

MeiraGTx Announces Poster Presentation at the 2023 American Society of Gene and Cell Therapy (ASGCT) Spotlight on Immuno-Oncology

Jul 19, 2023, 8:30 AM EDT - 3 years ago

MeiraGTx Announces its Wholly-Owned Gene Therapy Manufacturing Facility in Shannon, Ireland has Received Commercial MIA Authorization for QC Testing

Jun 27, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Holdings Transcript: Study Update

Jun 27, 2023, 7:30 AM EDT - 3 years ago

MeiraGTx Announces Positive Clinical Data from the AQUAx Phase 1 Clinical Study of AAV2-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

Jun 22, 2023, 4:01 PM EDT - 3 years ago

MeiraGTx to Present 12-month Data from All Cohorts of the Completed Phase 1 AQUAx Clinical Study and an Update on the Company's Recently Initiated Phase 2 Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Tuesday, June 27,

May 11, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Reports First Quarter 2023 Financial and Operational Results

May 3, 2023, 8:30 AM EDT - 3 years ago

MeiraGTx Announces $60 Million Private Placement of Ordinary Shares

Apr 21, 2023, 8:30 AM EDT - 3 years ago

MeiraGTx Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

Mar 14, 2023, 8:00 AM EDT - 3 years ago

MeiraGTx Reports Fourth Quarter and Full Year 2022 Financial and Operational Results

Dec 13, 2022, 8:00 AM EST - 3 years ago

MeiraGTx Holdings Transcript: Study Update

Dec 8, 2022, 4:30 PM EST - 3 years ago

MeiraGTx to Present Clinical Data from Phase 1 Trial of AAV-hAQP1 for Radiation-Induced Xerostomia on Tuesday, December 13, 2022

Oct 4, 2022, 8:00 AM EDT - 3 years ago

MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress

Oct 1, 2022, 10:00 AM EDT - 3 years ago

Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)

Sep 16, 2022, 2:00 AM EDT - 3 years ago

MeiraGTx's Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government

Aug 11, 2022, 8:30 AM EDT - 4 years ago

MeiraGTx Reports Second Quarter 2022 Financial and Operational Results

Aug 3, 2022, 8:00 AM EDT - 4 years ago

MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities

Jun 28, 2022, 8:00 AM EDT - 4 years ago

MeiraGTx Holdings Transcript: Study Result

Jun 28, 2022, 7:00 AM EDT - 4 years ago

MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) compared to

MGTX Apr. 25 at 6:22 PM

2 · Reply

slinghook67 Apr. 24 at 5:02 PM

0 · Reply

ErnieWorthing84 Apr. 24 at 4:00 PM

0 · Reply

focafoca99 Apr. 24 at 1:54 PM

$MGTX formalizes the initial closing of its Hologen collaboration covering neuro programs, delivery-device rights, and manufacturing arrangements.

0 · Reply

ErnieWorthing84 Apr. 24 at 9:49 AM

0 · Reply

slinghook67 Apr. 24 at 2:22 AM

0 · Reply

ErnieWorthing84 Apr. 23 at 10:04 AM

$MGTX CBER candidate… https://x.com/houmanhemmati/status/2047172768488378835

1 · Reply

erevnon Apr. 22 at 1:56 PM

Piper Sandler maintains MeiraGTx Holdings $MGTX at Overweight and raises the price target from $26 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

ErnieWorthing84 Apr. 22 at 11:54 AM

$MGTX https://x.com/medtechmd/status/2046910898217029861

0 · Reply

StreetwiseReports Apr. 20 at 8:07 PM

0 · Reply

StreetwiseReports Apr. 20 at 6:15 PM

Company Wins Back Promising Eye Disease Drug and Eyes Two Product Launches by 2028 https://ow.ly/Fo5Y50YMSUz MeiraGTx Holdings plc. ( $MGTX ) reported three-year durability data for AAV-hAQP1 in radiation-induced xerostomia, the reacquisition of filing-ready XLRP asset bota-vec from Johnson & Johnson, and a US$100M, according to an H.C. Wainwright research note.

0 · Reply

ErnieWorthing84 Apr. 20 at 1:11 PM

$MGTX https://x.com/EpochSwing/status/2046213816854130695

1 · Reply

vu_jade Apr. 17 at 7:19 PM

$MGTX threw on some May 15, $20 calls

1 · Reply

ErnieWorthing84 Apr. 17 at 4:20 PM

$MGTX Volume still raging

0 · Reply

ErnieWorthing84 Apr. 17 at 12:47 PM

$MGTX https://www.linkedin.com/posts/houman-david-hemmati-md-phd-aa0486_ophthalmology-podcast-lifesciences-activity-7440571405995503616-2lLS?utm_source=share&utm_medium=member_desktop&rcm=ACoAAA-izPIBXISQ360qmHAvSKAoz0ecqKOipGs

0 · Reply

AimSmall Apr. 17 at 12:30 PM

$MGTX RBC Raises to $24 from $16

0 · Reply

Mikelonggggggggg Apr. 17 at 11:48 AM

$ACAA $MGTX

0 · Reply

dgbio Apr. 17 at 5:51 AM

$MGTX Beacon, the only direct competior with a P3 study in XLRP, uses only LLVA as a primary endpoint. LLVA change was highly positive for bota-vec: 4.75 ETDRS letters difference with p=0.003.

0 · Reply

Helpmrwizard Apr. 17 at 3:56 AM

$MGTX I can’t wait to learn which institutions are participating in the 100 million

0 · Reply

ErnieWorthing84 Apr. 16 at 8:55 PM

$MGTX I really wonder what this “maze.” Even people with 20/20 will have variability navigating an actual maze.

0 · Reply

notreload_ai Apr. 16 at 8:00 PM

$MGTX stock fell after $100M share sale to raise cash. Money will fund gene therapy drugs and future launches. https://notreload.xyz/xy/meiragtx-stock-drops-on-100m-offering-bota-vec-deal/

0 · Reply

Gan1729 Apr. 16 at 7:21 PM

$MGTX Banknof America increases price target to $19.. 😎

1 · Reply

Market Cap	751.75M
Revenue (ttm)	81.39M
Net Income (ttm)	-114.20M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140.31%
Debt to Equity Ratio	-8.58

Volume	673,400
Avg Vol	714,294
Day's Range	N/A - N/A
Shares Out	81.45M
Stochastic %K	15%
Beta	1.27
Analysts	Strong Sell
Price Target	$27.88